Senseonics Appoints Steven V. Edelman, MD to its Board of Directors
GERMANTOWN, Md.--(BUSINESS WIRE)--
Senseonics Holdings, Inc. (NYSE-MKT:SENS), a medical technology company
focused on the development and commercialization of a long-term,
implantable continuous glucose monitoring (CGM) system for people with
diabetes, today announced that Steven Edelman, MD, clinical professor of
medicine at the University of California San Diego-Veterans Affairs
Healthcare System, has been appointed to its Board of Directors,
effective September 2, 2016.
“Dr. Edelman has been a leader and an innovator in the diabetes field
for decades and we are thrilled to now have his perspective and
contribution to our board of directors,” said Tim Goodnow, President and
Chief Executive Officer of Senseonics. “His expertise in clinical
research, application and education, as well as his passion for patient
advocacy will be invaluable as we build Senseonics into a leader within
the diabetes management market.”
Dr. Edelman is a clinical professor of medicine in the Division of
Endocrinology, Diabetes & Metabolism at the University of California at
San Diego and the Veterans Affairs Healthcare System of San Diego and
the director of the Diabetes Care Clinic VA Medical Center. His research
concentrates on developing, testing, and evaluating new technologies and
pharmaceutical agents for the treatment of type 1 and type 2 diabetes,
with a focus that includes glucose sensing technologies, clinical
utilization of continuous glucose monitoring and effective use of
anti-diabetic agents.
In 2011, Dr. Edelman received the Distinction in Endocrinology award by
the American Association of Clinical Endocrinologists, and in 2009, he
was awarded the Diabetes Educator of the year by the American Diabetes
Association. Dr. Edelman was also recently named among the top 1% of
endocrinologists in the United States by US News and World Report.
In addition, Dr. Edelman has authored more than 200 articles and five
books. Dr. Edelman was the valedictorian of his medical class at the
University of California at Davis, and completed his Endocrinology
fellowship at the Joslin and Lahey Clinics in Boston as well as a
research fellowship at the University of California at San Diego. As the
founder and director of Taking Control of Your Diabetes, a
not-for-profit organization with the goal of educating, motivating and
engaging people with diabetes and their caregivers, Dr. Edelman has
improved the lives of hundreds of thousands of people living with
diabetes.
“I look forward to working with the Senseonics team as we share the same
commitment to improve the lives of people with diabetes,” said Dr.
Edelman. “An implantable CGM system that provides the user with accurate
and reliable readings for up to 6 months is an incredible advance in the
effort to improve the lives of millions of people living with diabetes.
I think the Company has only scratched the surface of what’s possible
and I’m excited to help guide the team on behalf of the diabetes
community.”
About Senseonics
Senseonics
Holdings, Inc. is a medical technology company focused on the
design, development and commercialization of glucose monitoring products
designed to help people with diabetes confidently live their lives with
ease. Senseonics’ first generation CGM system, Eversense®, includes a
small sensor, smart transmitter and mobile application. Based on
fluorescence sensing technology, the sensor is designed to be inserted
subcutaneously and communicate with the smart transmitter to wirelessly
transmit glucose levels to a mobile device. After insertion, the sensor
is designed to continually and accurately measure glucose levels. For
more information on Senseonics, please visit www.senseonics.com.
Forward Looking Statements
Certain statements contained in this press release, other than
statements of fact that are independently verifiable at the date hereof,
may constitute “forward-looking statements.” These forward-looking
statements reflect Senseonics’ current views about its plans,
intentions, expectations, strategies and prospects, which are based on
the information currently available to Senseonics and on assumptions
Senseonics has made. Although Senseonics believes that its plans,
intentions, expectations, strategies and prospects as reflected in or
suggested by those forward-looking statements are reasonable, Senseonics
can give no assurance that the plans, intentions, expectations or
strategies will be attained or achieved. Furthermore, actual results may
differ materially from those described in the forward-looking statements
and will be affected by a variety of risks and factors that are beyond
Senseonics’ control. Other risks and uncertainties are more fully
described in the section entitled “Risk Factors” in Senseonics Holdings,
Inc.’s Annual Report on Form 10-K filed with the Securities and Exchange
Commission on February 19, 2016, the Quarterly Report on Form 10-Q filed
with the SEC on August 9, 2016 and its other SEC filings. Existing and
prospective investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. The
statements made in this press release speak only as of the date stated
herein, and subsequent events and developments may cause Senseonics’
expectations and beliefs to change. Unless otherwise required by
applicable securities laws, Senseonics does not intend, nor does it
undertake any obligation, to update or revise any forward-looking
statements contained in this news release to reflect subsequent
information, events, results or circumstances or otherwise. While
Senseonics may elect to update these forward-looking statements publicly
at some point in the future, Senseonics specifically disclaims any
obligation to do so, whether as a result of new information, future
events or otherwise, except as required by law.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160906006539/en/
Senseonics Holdings, Inc.
INVESTOR CONTACT
R. Don Elsey
Chief
Financial Officer
301.556.1602
[email protected]
Source: Senseonics Holdings, Inc.